HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024

Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations 


New data build upon the growing body of clinical evidence supporting non-invasive FFRCT technology and plaque analysis in the diagnosis and management of coronary artery disease

MOUNTAIN VIEW, Calif. — Oct. 14, 2024 HeartFlow, the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will present seven-year data from the ADVANCE-DK study, a subset from the larger ADVANCE Registry, which evaluated utility and clinical outcomes of HeartFlow’s AI-enabled FFRCT and Plaque Analysis in clinically stable, symptomatic patients with coronary artery disease (CAD). Data from the ADVANCE-DK study and other clinical studies will be presented at the 36th annual Transcatheter Cardiovascular Therapeutics® (TCT) conference, which will take place October 27-30, 2024 in Washington, D.C. 

“The ADVANCE registry helps us better understand whether more complete revascularization, as defined by FFRCT, is associated with improved long-term cardiovascular outcomes,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer of HeartFlow. “Three-year data from this registry confirmed that patients with both abnormal FFRCT and high plaque burden had two-and-a-half to three times greater risk of adverse cardiac events compared to patients with only abnormal FFRCT or high plaque volume. We are excited to present seven-year data and build on our body of evidence demonstrating FFRCT and AI-enabled plaque assessment as non-invasive approaches which can help physicians better quantify CAD risk in their patients.”

At TCT, HeartFlow will also present:

  • Late-breaking data evaluating the capacity of FFRCT and coronary computed tomography angiography (CCTA) to rule out significant lesions in high-risk non-ST elevation acute coronary syndromes (NSTE-ACS).
  • Data from FUTURE-AS, an international, prospective, multicenter registry of patients with severe aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR) being assessed for CAD with CCTA and FFRCT.
  • New data from FASTTRACK-CABG, a single-arm, multicenter, prospective study assessing safety and feasibility of bypass surgery in patients with complex CAD solely based on CCTA combined with FFRCT
  • Data highlighting the value for pre-procedural planning of combining FFRCT, virtual percutaneous coronary intervention (PCI), and myocardial mass.
  • Analysis of initial FFRCT-based virtual PCI for pre-procedural planning in the U.S. 

 

Details of each presentation are as follows:

Title: Completeness of Revascularization by FFRCT and Long-term Prognosis in Stable Angina: A Seven-Year Follow-up of the ADVANCE-DK Registry
Presenter: Kristian Taekker Madsen, M.D., Ph.D.
Date: Sunday, October 27, 2024
Time: 7:30-8:45 AM EDT
Session: TCT WorldLink Forum: Best Global Research in Coronary Imaging
Location: Presentation Theater 3, Innovation & Exhibit Hall (Halls A-C)

Title: TCT 288: Comparative Analysis of FFR Derived From CCTA, Murray Law-Based Quantitative Flow Ratio and Quantitative Flow Ratio at Sequential Side Branches in Patients With Complex CAD: Insights From the FASTTRACK CABG Study
Presenter: Kotaro Miyashita, M.D.
Date: Sunday, October 27, 2024
Time: 9:00-9:50 AM EDT
Session: Moderated Abstracts Station 2
Location: Innovation & Exhibit Hall (Halls A-C)

Title: TCT 172: Usefulness of FFRCT to Exclude Hemodynamically Significant Lesions in High-Risk NSTE-ACS 
Presenter: Georgios Tzimas, M.D.
Date: Monday, October 28, 2024
Time: 4:00-5:30 PM EDT
Session: Moderated Abstracts Station 2
Location: Innovation & Exhibit Hall (Halls A-C)

Title: TCT 830: Feasibility and Utility of Anatomical and Physiological Evaluation of Coronary Disease With Cardiac CT in Severe Aortic Stenosis (FUTURE-AS Registry)
Presenters: Abdul Rahman Ihdayhid, M.D., Ph.D.
Moderators: Philippe PM Garot, M.D., Marie-France Poulin, M.D.
Date: Tuesday, October 29, 2024
Time: 8:00-9:00 AM EDT
Session: TAVR and CAD – 1
Location: Moderated Abstracts Station 5, Innovation & Exhibit Hall (Halls A-C)


Title:
TCT 221: Coronary Computed Tomography Angiography-Guided Bifurcation Percutaneous Coronary Intervention: Role of FFRCT Virtual PCI and Myocardial Mass for Pre-Procedural Planning
Presenters: Pedro Carvalho, M.D.
Moderators: Hector M. Garcia-Garcia, M.D., Ph.D., John J. Lopez, M.D.
Date: Tuesday, October 29, 2024
Time: 2:00-3:00 PM EDT
Session: Anatomy-derived Coronary Physiology – 2
Location: Moderated Abstracts Station 2, Innovation & Exhibit Hall (Halls A-C)


Title:
TCT 96: Coronary Computed Tomography Angiography for Percutaneous Coronary Intervention: Initial US Experience With FFRCT-Based Virtual PCI for Pre-Procedural Planning
Presenters: Pedro Carvalho, M.D.
Moderators: Louis A. Cannon, M.D., Christopher Irobunda. M.D.
Date: Wednesday, October 30, 2024
Time: 9:00-9:56 AM EDT
Session: Novel Percutaneous Techniques
Location: Moderated Abstracts Station 6, Innovation & Exhibit Hall (Halls A-C)


Heartflow invites attendees to a lunch symposium, “Utilizing Coronary CTA & HeartFlow AI to Non-Invasively Assess Anatomy, Physiology and Plaque,” led by a panel of well-respected physicians including Ziad A. Ali, M.D., Suzanne J. Baron, M.D., Nick Curzen, M.D., Jimmy Lee Kerrigan, M.D. and Akiko Maehara, M.D. The symposium will take place on Tuesday, October 29, 2024, from 12:30-1:30 PM EDT in the FDA Theater, Innovation & Exhibit Hall (Halls A-C). 

 

About HeartFlow, Inc.

HeartFlow is transforming precision coronary care with the only AI-powered, non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guideline, HeartFlow continues to advance the diagnosis and management of CAD. HeartFlow’s suite of non-invasive technologies includes its FFRCT Analysis, RoadMap™ Analysis, and Plaque Analysis. More than 500 peer-reviewed publications have validated our approach and more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.heartflow.com.

 

Media Contact

Elliot Levy
media@heartflow.com

Investor Contact

Nick Laudico
VP of Business Development and Investor Relations
nlaudico@heartflow.com

 

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.